Skip to content

Released Feb 28, 2025, before the open

10-K filed Feb 28, 2025, 59 days after period end · 0001628280-25-008884

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$2.18Mderived— vs Q4 2023+944.5% vs Q3 2024
Net Income-$42.28MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$44,222,000N/M
Operating Cash Flowderived$16,245,000N/M
Free Cash Flowderived$14,454,000N/M
Margins · derived
Operating margin-2025.7%
Net margin-1936.6%

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Revenue$2.18M$0.00——
Net Income-$42.28M-$65.64M-$39.28M-$62.91M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR